Therapeutically, targeting of YTHDF1 in vitro and in vivo with vesicle-like nanoparticle (VNP)-encapsulated siYTHDF1 or YTHDF1 selective inhibitor salicylic acid C (SAC) suppressed tumor growth and synergistically enhanced OXA and 5-FU treatment efficacy in vivo. This evidence concerns the gene YTHDF1 and neoplasm.